What's New
News
One-Night Performance of Acclaimed Play UnRavelled Examines Art, Science, and Dementia
AFTD staff and Board members attended a performance of the play UnRavelled at the San Francisco Conservatory…
AFTD and AviadoBio Discuss Therapeutic Treatment Protocols for FTD
AFTD recently spoke with AviadoBio Chief Executive Officer Lisa Deschamps about her colleagues’ work to develop a…
Groundbreaking Drug That Slows Progression of Alzheimer’s Receives Full FDA Approval
The U.S. Food and Drug Administration (FDA) has, for the first time, fully approved a drug that…
Dr. Chiadi Onyike Named AFTD Medical Advisory Council Chair-Elect
During their annual meeting at the 2023 Education Conference, AFTD’s Board of Directors named Chiadi Onyike, MD,…
Wave Life Sciences Ends FTD/ALS Trial of WVE-004
Yesterday, Wave Life Sciences announced that it ended its FOCUS-C9 clinical trial for the drug WVE-004, which…
AFTD and Alector Discuss FTD Therapeutic Development
AFTD recently spoke with Alector Chief Medical Officer Gary Romano, MD, PhD, about his colleagues’ work to…
“Coming Together for Change”: AFTD Volunteers Gather Virtually
“Calling all AFTD volunteers!” Recently, the AFTD Volunteer and Events Departments co-hosted virtual gatherings for our AFTD…
2023 Hope Rising Benefit Raises Crucial Funds for AFTD’s Mission
(L-R: Hope Rising Benefit Co-Chair David Zaslav, AFTD CEO Susan L-J Dickinson, AFTD Board member Kristin Holloway,…
AFTD Now Offering CME Credits to Healthcare Professional Webinar Attendees
As part of an ongoing organizational effort to provide vital FTD education to healthcare professionals, AFTD held…
Spotlight on… Julie Kelly, AFTD Board of Directors
Growing up, Julie Kelly was like a third sister to her best friends, identical twins Cathy Pfeifer…
English 
Spanish (Mexico) 
French 
German 
Swedish 
Portuguese 
Italian 
Dutch 
Danish 
Polish 
Spanish (Spain)